The challenges of adherence to infant feeding choices in prevention of mother-to-child transmission of HIV infections in South East Nigeria

Figures & data

Table 1 Sociodemographic characteristics of participants, N=556

Variables	n (%)
Age, years
<20	1 (0.2)
21–25	134 (24.1)
26–30	201 (36.2)
31–35	182 (32.7)
36–40	38 (6.8)
Marital status
Married	536 (96.4)
Single	16 (2.9)
Separated	3 (0.5)
Divorced	1 (0.2)
Educational status
None	45 (8.1)
Primary	203 (36.5)
Secondary	285 (51.3)
Tertiary	23 (4.1)
Employment status
Employed	398 (71.6)
Unemployed	158 (28.4)
Residence
Urban	151 (27.2)
Rural	405 (72.8)
Parity
1	140 (25.2)
2–4	414 (74.4)
≥5	2 (0.4)

Table 2 Infant feeding practice (within 6 months of life), time of decision, disclosure of status, and reasons for mixed feeding

Variables	n (%)
Infant feeding practice, N=556
Exclusive breastfeeding	510 (91.7)
Exclusive formula feeding	4 (0.7)
Mixed feeding	42 (7.6)
Time of decision, N=556
Antepartum	556 (100.0)
Intrapartum	0 (0.0)
Postpartum	0 (0.0)
Who made choice, N=556
Parturient (woman) only	209 (37.6)
Partner (husband) only	7 (1.3)
Jointly	340 (61.1)
Disclosure of status, N=556
Yes	496 (89.2)
No	60 (10.8)
Reasons for mixed feeding, N=42
Pressure from family members	18 (42.8)
Cultural practices	12 (28.5)
Nondisclosure	4 (9.5)
Peer pressure	2 (4.8)
Ignorance of the risk	2 (4.8)
Inability to meet AFASS for EFF	1 (2.4)
Breast problems	1 (2.4)
Job commitment	1 (2.4)
Maternal medical conditions	1 (2.4)
Duration of breastfeeding, N=552
<1 year	107 (19.4)
1 year	445 (80.6)
>1 year	0 (0.0)

Abbreviations: AFASS, acceptable feasible affordable sustainable and safe; EFF, exclusive formula feeding.

Table 3 Maternal highly active antiretroviral therapy, indication and period on highly active antiretroviral therapy, N=556

Variables	n (%)
Received highly active antiretroviral therapy
Yes	556 (100.0)
No	0 (0.0)
Indication
Prophylaxis	387 (69.6)
Treatment	169 (30.4)
Period
Antepartum and intrapartum only	4 (0.7)
Antepartum, intrapartum, and postpartum (during breastfeeding)	383 (68.9)
Continued after breastfeeding	169 (30.4)

Table 4 Newborn nevirapine prophylaxis and duration, N=556

Variables	n (%)
Received nevirapine
Yes	556 (100.0)
No	0 (0.0)
Duration
<6 weeks	0 (0.0)
6 weeks only	556 (100.0)
>6 weeks	0 (0.0)